<DOC>
	<DOCNO>NCT01162135</DOCNO>
	<brief_summary>The purpose study assess effectiveness dioxin prohibit prostate cancer progression measure PSADT ( prostate-specific antigen double time ) .</brief_summary>
	<brief_title>Digoxin Recurrent Prostate Cancer</brief_title>
	<detailed_description>This pilot phase II , open label single center study assess efficacy digoxin inhibit PCa progression measure PSADT . The participant take study drug digoxin , approve FDA treatment CHF , 125 250 mcg orally daily , titrate level 0.8 - 2 ng/ml total 6 cycle ( 4 weeks/cycle ) . The low dose digoxin ( 125 mcg/day ) chosen serum level reach 0.8 ng/ml already . Patients may continue another 6 cycle evident clinical benefit .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>There must confirm biochemical progression . Biochemical progression define three rise PSA level , PSA determine least 4 week apart , PSA value increase &gt; 0.2 ng/ml . Baseline PSA must determine within 4 week study entry . At least 3 PSA value necessary prior study entry calculate PSA doubling time ( PSADT ) calculator . Men history radical prostatectomy require baseline PSA &gt; 1 ng/ml . Men treat primary radiation therapy require baseline PSA &gt; 2 ng/ml great 150 % rise postradiation nadir . PSA double time must 6 24 month . All treatment include intermittent hormonal therapy must discontinue &gt; 6 month prior study entry . No clinical radiological evidence distant metastasis ECOG &lt; 2 adequate organ function Men history radical prostatectomy require baseline PSA &gt; 1 ng/ml . Men treat primary radiation therapy require baseline PSA &gt; 2 ng/ml great 150 % rise postradiation nadir Baseline PSA must determine within 4 week study entry . At least 3 PSA value necessary calculate PSA double time via PSADT calculator : http : //www.mskcc.org/mskcc/applications/nomograms/PSADoublingTime.aspx . PSA double time must 6 24 month . All previous local modality treatment , include radiation surgery , must discontinue least 8 week prior treatment study . Patients may receive prior systemic chemotherapy , hormonal therapy , biologic vaccine therapy . All systemic treatment must discontinue &gt; 6 month prior study entry . Patients receive intermittent hormonal therapy rise PSA state consider eligible testosterone level 150ng/dl treatment discontinue &gt; 6 month agree additional injection study drug . No clinical radiological evidence distant metastasis ( exclude prostascint scan/PET absence radiographic disease Bone scan , CT scan MRI use ) . Lymph node 2 cm size allow study . ECOG &lt; 2 Karnofsky Performance status &gt; 70 % within 14 day register protocol therapy ( Appendix B ) Normal organ function acceptable initial laboratory value : Absolute neutrophil count ≥ 1 x 109/L Platelets &gt; 50 x 109/L Creatinine &lt; 1.5 mg/dL Bilirubin &lt; 1.5 X ULN ( institutional upper limit normal ) AST ( SGOT ) ALT ( SGPT ) ≤ 1.5 x ULN Willingness use adequate method contraception throughout study participation least 3 month complete therapy Metastatic disease currently active second malignancy History Sinus Node Disease AV Block , Accessory AV Pathway ( WolffParkinsonWhite Syndrome ) , history Acute Myocardial Infarction . Electrolyte imbalance ( hypokalemia , hypo hypercalcemia , hypomagnesemia ) Severe pulmonary disease hypoxia Medical condition uncontrolled hypertension , uncontrolled diabetes mellitus , active infectious hepatitis , type A , B C , hypothyroidism hyperthyroidism , would , opinion investigator , make protocol unreasonably hazardous . Major thoracic abdominal surgery within prior 3 week . Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . Use prohibit concomitant medication : The washout period least 2 week start study . Insufficient time last prior regimen radiation exposure : Systemic therapy prostate cancer within 28 day prior digoxin ; strontium89 within 12 week ; bicalutamide within 6 week . Persistent Grade &gt; 2 treatmentrelated toxicity prior therapy History digoxinrelated drug induce anaphylactic reaction Receipt another investigational agent within 6 month study entry . Patient must recover side effect prior investigational therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Digoxin</keyword>
	<keyword>Recurrent Prostate Cancer</keyword>
	<keyword>Prostate Specific Antigen</keyword>
</DOC>